Professor Charlie Gourley on Advances in Ovarian Cancer Maintenance Therapy

Charlie Gourley, PhD, MBChB, chair and honorary consultant in Medical Oncology at Edinburgh Cancer Research Centre in the United Kingdom, discuses olaparib (Lynparza), which was recently investigated in a phase II Study 19 trial versus placebo as a maintenance therapy for patients with relapsed platinum-sensitive serous ovarian cancer.

The drug really works, says Gourley. The study was designed to look at progression-free survival (PFS), and, unequivocally, it clearly showed that this drug improved PFS, he says.